Patents Examined by Mark L. Shibuya
  • Patent number: 10807973
    Abstract: New compounds and a method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, including administering compound of the formula (I) or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or, if applicable, a corresponding diastereomer thereof, wherein: A is a 5-oxazolyl residue or a pyridine-4-yl residue, R1 is selected from the group consisting of fluoro, chloro and methoxy; B is selected from the group consisting of a residue of formula (II), (III) and (IV) wherein, “*” denotes the point of attachment to the remainder of the molecule, and R2, R2?, R2?, R3, R3?, R3?, R4, R4?, R4?, R5, R5? and R5? are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 4 carbon atoms, trifluoromethyl, 2,2,2-trifluoroethyl, methylsulfanyl, ethylsulfanyl, methylsulfonyl, ethylsulfonyl, difluoromethoxy, trifluoromethoxy, fluoro, bromo, chloro, methoxy, ethoxy, propoxy, butoxy, hydroxy and amino.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: October 20, 2020
    Assignee: ENDOGENA THERAPEUTICS, INC.
    Inventors: Matthias Steger, Alex Mueller, Bernhard Fasching, Daphna Mokady
  • Patent number: 10807970
    Abstract: The present invention relates to tetrahydropyran and thiopyran derivatives having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 20, 2020
    Assignee: ESTEVE PHARMACEUTICALS, S.A.
    Inventors: Monica Garcia-Lopez, Carmen Almansa-Rosales, Ana Virginia Llorente-Fernandez, Ute Christmann, Sergio Rodriguez Escrich
  • Patent number: 10792283
    Abstract: The present disclosure provides selective phosphoinositide 3-kinase inhibitors of formula (A), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated by one or more P13K isoforms, such as PI3K delta (PI3K?). The present disclosure further provides methods of inhibiting phosphoinositide 3-kinase inhibitors using these compounds for treatment of disorders related to phosphatidylinositol 3-kinase activity.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 6, 2020
    Assignee: HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD.
    Inventor: Xiaolin Hao
  • Patent number: 10786507
    Abstract: Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 29, 2020
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Hao Chen, Xiaochen Pan
  • Patent number: 10786513
    Abstract: A compound for use in the treatment of itch is provided, wherein the compound comprises the general formula (1a), general formula (1b) or general formula (1c). The compounds of the invention are positive allosteric ?2 and/or ?3 GABAA receptor modulators.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: September 29, 2020
    Assignee: UNIVERSITAT ZURICH
    Inventors: Hanns Ulrich Zeilhofer, William Ralvenius
  • Patent number: 10787437
    Abstract: The present invention relates to processes for preparing pyrazole derivatives of Formula (I) and salts and pharmaceutical compositions of the salts thereof, useful as modulators of 5-HT2A serotonin receptor activity. The present invention also relates to intermediates used in the processes, and their preparation. The present invention also relates to salts of compounds of Formula (I) and pharmaceutical compositions thereof.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: September 29, 2020
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Ashwin M. Krishnan, Tawfik Gharbaoui
  • Patent number: 10787420
    Abstract: A benzimidazole compound and a preparation method thereof. Various substituted benzimidazoles are synthesized by a SN2 reaction and a cyclization reaction. Namely, o-fluorinated aryl-N,N-dimethyl-formamidine and primary amine are subjected to an cyclization by a one-pot reaction, wherein a fluorine atom is substituted by an amino, and then dimethylamine is eliminated, thus forming the product. The method does not require the use of any metal catalyst and/or any toxic reagent, and has a specific selectivity. No isomer exists in the reaction product.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 29, 2020
    Assignees: SHANDONG ENGINEERING AND TECHNOLOGY INSTITUTE OF LUNAN COAL CHEMICAL ENGINEERING, ZAOZHUANG UNIVERSITY, SHANDONG JITIAN AROMA CHEMICAL CO LTD, Asset (Suzhou) Pharma Co., Ltd.
    Inventors: Xuejing Liu, Ying Han, Liang Yang
  • Patent number: 10780089
    Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: September 22, 2020
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: David McGowan, Pierre Jean-Marie Bernard Raboisson, Werner Embrechts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jaromir Vlach
  • Patent number: 10752612
    Abstract: Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 25, 2020
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Timothy Gahman, Andrew Shiau
  • Patent number: 10752596
    Abstract: The invention provides a compound having a GLUT9 inhibitory activity. The compound is of Formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: August 25, 2020
    Assignee: JAPAN TOBACCO INC.
    Inventors: Hironobu Nagamori, Tatsuya Nishimaru, Masaki Takagi, Ikuo Mitani, Yuichi Nakagawa
  • Patent number: 10745383
    Abstract: Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: August 18, 2020
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
    Inventors: Na Zhao, Shulong Wang, Xijie Liu, Yuandong Hu, Hui Zhang, Hong Luo, Yong Peng, Yongxin Han, Xiquan Zhang, Hongjiang Xu
  • Patent number: 10660881
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: May 26, 2020
    Assignee: Novartis AG
    Inventors: Ha-Soon Choi, James Paul Lajiness, Srinivasa Reddy Natala, Bao Nguyen, Hank Michael James Petrassi, Zhicheng Wang
  • Patent number: 10562926
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 18, 2020
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 10383863
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: August 20, 2019
    Assignee: Novartis AG
    Inventors: Ha-Soon Choi, James Paul Lajiness, Srinivasa Reddy Natala, Bao Nguyen, Hank Michael James Petrassi, Zhicheng Wang
  • Patent number: 10195156
    Abstract: The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: February 5, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Kerry E. Benenato, William Butcher
  • Patent number: 7964414
    Abstract: The present invention provides a biosensor, wherein non-specific adsorption on a surface that does not retain a physiologically active substance (reference unit) is suppressed. The biosensor of the invention includes a substrate having at least two types of surfaces on a single plane, wherein at least one of the surfaces does not retain a physiologically active substance, and wherein at least two types of hydrophilic compounds with different molecular weights are bound to the surface that does not retain a physiologically active substance.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: June 21, 2011
    Assignee: Fujifilm Corporation
    Inventors: Toshihide Ezoe, Taisei Nishimi, Yukou Saito
  • Patent number: 7943398
    Abstract: Embodiments of the invention relate generally to ferromagnetic microdisks, methods of detecting target bioanalyte using ferromagnetic microdisks, and kits (such as for using in the laboratory setting) containing the reagents necessary to make, and/or use ferromagnetic microdisks for bioanalyte detection, depending on the user's planned application. The methods and products allow the fabrication of ferromagnetic microdisks, and their use in the detection of biological molecules with high sensitivity, little or no signal decay, improved safety, convenience, and lowered cost for use and disposal.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: May 17, 2011
    Assignee: Intel Corporation
    Inventor: Chang-Min Park
  • Patent number: 7910383
    Abstract: The invention concerns a method for preparing a molecular fingerprint comprising sites for identifying at least one target molecule, the fingerprint being obtained from at least one master molecule of polymeric type, called master polymer. The invention is characterized in that the master polymer is different from the target molecule(s), and is capable of being eliminated by degradation and/or washing, and that at least 5% in number of monomer units constituting the master polymer are involved in the formation of the sites for identifying the target molecule(s).
    Type: Grant
    Filed: July 4, 2006
    Date of Patent: March 22, 2011
    Assignee: Polyintell
    Inventors: Sami Bayoudh, Kaynoush Naraghi, Michel Arotcarena
  • Patent number: 7863005
    Abstract: It is an object of the present invention to provide a simple, reliable and low-invasive method to detect perilymph fistulas. The present invention provides a method for detecting a perilymph fistula, which comprises detecting the existence of Cochlin in body fluid existing in the middle ear.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: January 4, 2011
    Assignee: Nippon Medical School Foundation
    Inventors: Tetsuo Ikezono, Toshiaki Yagi, Akira Omori
  • Patent number: 7842513
    Abstract: This invention provides methods and compositions for testing for pregnancy and non-pregnancy in ungulates and non-hoofed ruminates. The tests provided by this invention are useful during a time that coincides with the estrus cycle during which breeding occurs or the first estrus cycle after breeding of a non-pregnant animal. The tests provided by this invention are useful in estrus and ovulation synchronization programs, with pregnancy testing useful at a time allowing for resynchronization of non-pregnant animals within the first estrus cycle. The tests provided by this invention assay for the presence, absence, or level of a selected IFN-?-induced protein in a sample from a female animal. The tests of this invention are useful for testing cells, blood, plasma, serum, cells, milk, nasal secretions, ocular secretions, vaginal secretions, urine, and saliva samples. The tests provided by this invention are immunoassays.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: November 30, 2010
    Assignees: AspenBio Pharma, Inc., University of Wyoming
    Inventors: Mark Colgin, Diane Newman, Cathy Landmann, Jay W. Roth, Roger Hurst, Thomas R. Hansen, Kathleen Jeanette Austin